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Abstract
Clear signaling roles for ATP and adenosine have been
established in all tissues, including the eye. The magnitude
of signaling responses is governed by networks of enzymes;
however, little is known about the regulatory mechanisms of
purinergic signaling in the eye. By employing thin-layer chro-
matographic assays with 3H-labeled substrates, this study
aimed to evaluate the role of nucleotide homeostasis in the
pathogenesis of vitreoretinal diseases in humans. We have
identified soluble enzymes ecto-5′-nucleotidase/CD73, ade-
nylate kinase-1, and nucleoside diphosphate kinase in the vit-
reous fluid that control active cycling between pro-
inflammatory ATP and anti-inflammatory adenosine.
Strikingly, patients with proliferative form of diabetic retinop-
athy (DR) had higher adenylate kinase activity and ATP con-
centration, when compared to non-proliferative DR eyes and
non-diabetic controls operated for rhegmatogenous retinal
detachment, macular hole, and pucker. The non-parametric
correlation analysis revealed positive correlations between in-
travitreal adenylate kinase and concentrations of ATP, ADP,
and other angiogenic (angiopoietins-1 and -2), profibrotic
(transforming growth factor-β1), and proteolytic (matrix
metalloproteinase-9) factors but not erythropoietin and
VEGF. Immunohistochemical staining of postmortem human
retina additionally revealed selective expression of ecto-5′-nu-
cleotidase/CD73 on the rod-and-cone-containing photorecep-
tor cells. Collectively, these findings provide novel insights
into the regulatory mechanisms that influence purinergic sig-
naling in diseased eye and open up new possibilities in the
development of enzyme-targeted therapeutic approaches for
prevention and treatment of DR.
Key message
& Ecto-5′-nucleotidase/CD73 and adenylate kinase-1 circu-
late in human vitreous fluid.
& Adenylate kinase activity is high in diabetic eyes with
proliferative retinopathy.
& Diabetic eyes display higher intravitreal ATP/ADP ratio
than non-diabetic controls.
& Soluble adenylate kinase maintains resynthesis of inflam-
matory ATP in diabetic eyes
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Introduction
Diabetic retinopathy (DR) is a leading cause of vision impair-
ment and blindness among working age people in developed
countries, characterized by neuronal and glial dysfunctions;
cell death in retinal capillaries; vascular leakage; vessel
Electronic supplementary material The online version of this article
(doi:10.1007/s00109-016-1472-6) contains supplementary material,
which is available to authorized users.
* Gennady G. Yegutkin
gennady.yegutkin@utu.fi
1 Unit of Vitreoretinal Surgery, Department of Ophthalmology,
Helsinki University Central Hospital and University of Helsinki,
Helsinki, Finland
2 Cell Imaging Core, Turku Centre for Biotechnology, University of
Turku and Åbo Akademi University, Turku, Finland
3 MediCity Research Laboratory and Department of Medical
Microbiology and Immunology, University of Turku, Tykistökatu
6A, 20520 Turku, Finland
4 Department of Ophthalmology, Turku University Hospital,
Turku, Finland
J Mol Med (2017) 95:193–204
DOI 10.1007/s00109-016-1472-6
occlusion; retinal fibrosis; and in the proliferative form, inva-
sion of abnormal blood vessels from the retinal circulation,
growth of newly formed vessels (neovascularization), and
lymphangiogenesis [1–4]. Numerous factors, such as vascular
endothelial growth factor (VEGF) and angiopoietins (Ang),
neurotrophic mediators somatostatin and neurotrophins,
erythropoietin (EPO), tumor necrosis factor-α (TNF-α),
transforming growth factor-β1 (TGFβ1), and other cytokines
and chemokines, have been shown to be implicated in the
pathogenesis of DR [3–7]. Current treatments for DR include
systemic treatments of the classic risk factors (i.e., hypergly-
cemia and hypertension), anti-oxidant, anti-inflammatory and
laser therapies, intravitreal injections of anti-VEGF drugs or
corticosteroids, pars plana vitrectomy, and stem cell therapies
for repairing the injured retinal microvessels [3–5]. Further
development of preventional and interventional strategies
against DR requires better understanding of the exact mecha-
nisms underlying diabetes-induced microvascular, neurode-
generative, and inflammatory injuries.
ATP and other nucleotides and adenosine have emerged as
important regulators of ocular functions, particularly involved
in neuroprotection, intraocular pressure, immunomodulation,
vasodilatation, and retinal functioning [8–12]. ATP and other
purines are present in vitreous fluids (VFs) and aqueous hu-
mor, and their concentrations can be modulated in pathologi-
cal conditions such as dry eye disease [13], glaucoma [10, 14,
15], ischemia reperfusion [8], age-related macular degenera-
tion [16], and DR [17]. In diabetes mellitus, the basic cellular
defects in metabolism and hyperglycemia may lead to altered
intracellular and extracellular nucleotide levels, accompanied
by changes in signaling pathways in the pancreas and selected
tissues/organs, including eye [18].
Mostmodels of purinergic signaling depend on interactions
between distinct processes including (i) release of ATP and
other purines, (ii) triggering of signaling events via a series of
nucleotide- and nucleoside-selective receptors, and (iii) ecto-
enzymatic inactivation of purinergic agonists [19, 20].
General schemes of purine-converting pathways include nu-
cleoside triphosphate diphosphohydrolase-1 (NTPDase1, also
known as CD39), other enzymes of NTPDase and nucleotide
pyrophosphatase/phosphodiesterase families, ecto-5′-nucleo-
tidase/CD73 (eN/CD73), alkaline phosphatases, adenosine
deaminase, and backward ATP-regenerating enzymes adenyl-
ate kinase (AK) and nucleoside diphosphate kinase (NDPK)
[19, 21, 22]. Research over the past decade highlights the
central role for CD39-CD73 axis in controlling the balance
betweenATP, ADP, and adenosine in a wide range of diseases,
including endothelial barrier dysfunction and activation and
aggregation of platelets at sites of vascular injury, hypoxia,
and inflammation [20, 23, 24]. However, current knowledge
of regulatory pathways governing the duration and magnitude
of purinergic signaling in the eye remains rather scattered.
Previous research has been focused on the expression of
NTPDases and/or eN/CD73 in Müller glial cells of rodent
retina and their role in neurovascular coupling [11, 25], os-
motic cell swelling [26], and diabetes [12], as well as in rodent
and primate retinas [15], human retinal pigment epithelial
cells [27], and trabecular meshwork cells [28] in terms of the
control of intraocular pressure and cytoskeletal remodeling.
By employing thin-layer chromatographic (TLC) enzymat-
ic assays with 3H-labeled substrates, together with
immunodepletion and histochemical approaches, this study
aimed to evaluate the role of nucleotide homeostasis in the
pathogenesis of vitreoretinal diseases in humans. The results
obtained identify eN/CD73 and AK1 as key soluble enzymes
in the human VF, and further suggest their contribution to the
pathogenesis of DR, especially its sight-threatening form, pro-
liferative diabetic retinopathy (PDR).
Material and methods
Study design
Vitreous specimens from 228 patients recruited in the Unit of
Vitreoretinal Diseases (Helsinki University Central Hospital)
were available for analysis. They were sub-grouped as fol-
lows: non-diabetic eyes operated owing to non-vascular
vitreoretinal diseases, including rhegmatogenous retinal de-
tachment (RRD), quiescent idiopathic macular hole (MH) or
pucker, as well as diabetic group comprising of PDR and non-
PDR patients (Table 1). All vitrectomies were performed by a
vitreoretinal surgeon, as described elsewhere [6, 7] (Fig. 1).
The studies were conducted according to the principles of the
Declaration of Helsinki and approved by the Institutional
Review Board of the Helsinki University Central Hospital
and the Ethical Committee. A signed informed consent was
obtained from each participant. Additional information on
sample collection and processing can be found in the
Supplementary Material.
TLC analysis of purine-converting activities
ATPase, ADPase, eN/CD73, AK, NDPK, and adenosine de-
aminase were assayed by incubating the VF (8 μl) with 3H-
labeled and unlabeled ATP, ADP, AMP, and adenosine as
appropriate substrates. 3H-labeled nucleotides and nucleo-
sides were separated by TLC and then quantified by scintilla-
tion β-counting [29] or developed by autoradiography, as de-
scribed in the Supplementary Material.
Determination of intravitreal ATP, ADP, adenosine,
and other biomarkers
ATP, ADP, and adenosine were determined using enzyme-
coupled assays [17, 30]. For experimental details, see
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Supplementary Material. Matrix metalloproteinase-9 (MMP-
9) activity was assayed by gelatin zymography, while the con-
centrations of Ang-1, Ang-2, VEGF, EPO, and TGFβ1 were
determined using Enzyme-Linked Immunosorbent Assay
(ELISA) Kits, as described elsewhere [6].
Immunohistochemical analysis of eN/CD73 expression
in human retina
Cadaver eyeballs were enucleated 36–48 h postmortem from
two female donors without apparent eye diseases. The use of
postmortem human tissues has been approved by the Ethical
Committee of Turku University Hospital. Paraffin sections of
the retina were stained with rabbit α-CD73 antibody (D7F9A,
Cell Signaling Technology) or normal rabbit serum (NRS)
diluted in PBS at 1:1000, by using Vectastain® Elite ABC
Kit (Vector Laboratories, Burlingame, USA), according to
the manufacturer’s instructions. Tissues were counterstained
with Mayer’s hematoxylin and mounted with DPX Mountant
(Sigma). Bright-field microscopy images were captured using
Zeiss AxioVert-200 M microscope with AxioCam-MRc cam-
era using LD A-Plan ×20/0.30 objective (Zeiss GmbH,
Oberkochen, Germany).
Statistical analysis
Two-tailed Student’s t test and Mann-Whitney U test were
used to compare the levels of continuous variables in the di-
chotomous class variables according to the variable’s
distribution. Intravitreal eN/CD73 activity was normally dis-
tributed after square root transformation, and Ang-1 and Ang-
2 normal distribution was achieved after ln transformation. To
study the mean ranks of continuous variables, Kruskal-Wallis
test was used for all variables. Non-parametric Spearman’s
correlation coefficients were computed to investigate the
inter-correlations of continuous variables (SAS Institute.,
Cary, NC, USA). In case of comparative studies, the re-
searcher(s) analyzed the encoded vitreous samples provided
by the surgeon in a masked way, without knowing the clinical
status of the patients. The statistical significance levels were
denoted as *P < 0.05 and **P < 0.01.
Results
The identification of soluble eN/CD73 and AK1 enzymes
in the human vitreous fluid
This work was undertaken to characterize the pattern of purine
homeostasis in unique biological fluids collected from
vitrectomized eyes of the patients with various vitreoretinal
disorders. Figure 1 schematically outlines the principal design
of this study.
We took advantage of radio-TLC for autoradiographic
screening of purine-converting pathways. As shown in
Fig. 2a, VF from patients with RRD efficiently hydrolysed
[3H]AMP into [3H]adenosine (lane 2), while specific inhibitor
of eN/CD73 APCP [31] blocked this nucleotidase reaction
Table 1 Diabetes mellitus (DM),
age and gender distribution, and
purine concentrations among the
patients studied
Patients Non-diabetic Diabetic
RRD MH/pucker PDR Non-PDR
Number 112 31 40 46
Males/females 66/46 7/24 17/23 28/18
DM1/DM2 – – 23/17 9/37
Age, years 61.4 ± 1.1 68.7 ± 1.1 46.0 ± 3.0* 63.1 ± 2.1
Duration of DM, years – – 19.1 ± 1.7 15.0 ± 1.8
Vitreous ATP, nM 4.5 ± 0.7 3.1 ± 0.9 86.0 ± 33.1** 26.1 ± 14.8**
Vitreous ADP, nM 21.2 ± 3.3 13.7 ± 4.3 64.9 ± 20.1 23.1 ± 7.0
Vitreous ATP/ADP ratio 2.6 ± 0.5 1.6 ± 0.9 9.0 ± 6.4* 5.9 ± 1.5*
Vitreous adenosine, nM 1226 ± 106 (91) 1448 ± 250 (28) 1323 ± 377 (20) 1216 ± 191 (29)
Plasma ATP, nM 1170 ± 101 (95) 1389 ± 281 (31) 1186 ± 131 (27) 2100 ± 514 (30)
Plasma ADP, nM 990 ± 88 (95) 1122 ± 187 (31) 988 ± 127 (27) 1538 ± 346 (30)
Plasma Hb, mg/dL 4.5 ± 0.3 (95) 4.2 ± 0.5 (31) 4.4 ± 0.3 (27) 4.4 ± 0.5 (30)
Blood HbA1c, % – – 9.2 ± 0.5 (20) 8.4 ± 0.3 (20)
Vitreous ATP and ADP were assayed in all patients studied, while the levels of vitreous adenosine, plasma
nucleotides, and hemoglobin (Hb), as well as glycated hemoglobin A1c (HbA1c) in the whole blood were
determined in the indicated patient number, as specified in the parentheses. Data are presented as mean ± SEM
*P < 0.05 as compared with corresponding values from control RRD patients
**P < 0.01 as compared with corresponding values from control RRD patients
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(lane 3). In the presence of γ-phosphate-donating ATP, part of
[3H]AMP was converted into 3H-labeled ADP/ATP (lane 4),
whereas AK inhibitor Ap5A prevented this phosphotransfer
reaction (lane 5). A substantial band corresponding to
[3H]AMP can be detected after incubating the sample with
[3H]ADP (lane 7). However, the inhibition of [3H]ADP break-
down byAp5A (lane 8), together with the negligible [
3H]ATP-
hydrolyzing capability of VF (lane 11), indicates that intravit-
real nucleotide metabolism occurs through AK rather than
Btrue^ NTPDase activity. Moreover, the ability of VF to fur-
ther transphosphorylate [3H]ADP and ATP into [3H]ATP and
ADP suggests the existence of yet another nucleotide kinase,
NDPK (lane 9).
Consistent with the autoradiographic data, a direct quanti-
tative analysis confirmed the ability of VF to hydrolyse
[3H]AMP and also to phosphorylate both [3H]AMP and
[3H]ADP in an ATP-dependent manner. The employment of
[3H]ATP, [3H]ADP (in combination with Ap5A), and
[3H]adenosine as initial substrates revealed low but clearly
detectable ATPase activities in the VF from some (four out
of eight) patients and the absence of ADPase and adenosine
deaminase in all specimens studied (Fig. 2b). Importantly,
removal of potential microparticles or tissue debris by addi-
tional centrifugation and filtering the samples did not affect
the measured rates of [3H]AMP hydrolysis and phosphoryla-
tion (Fig. 2c).
To further identify the nature of these activities, VFs were
incubated with Protein-A Sepharose beads coupled to differ-
ent immunoglobulins. CD73-depleted VFs are characterized
by markedly diminished [3H]AMP-hydrolyzing capability,
thus confirming that CD73 accounts for more than 90 %
of intravitreal AMPase. Likewise, compared with mock-
treated controls, VF depleted of AK1 (but not of another
enzyme isoform AK2) were characterized by ∼65 % lower
rate of ATP-induced [3H]AMP phosphorylation (Fig. 2d).
The residual 35 % of activity might reflect either insufficient
depleting efficacy of anti-AK1 antibody or the co-existence
of other AK isoform(s). Collectively, our data identified
AK1 as a key soluble enzyme mediating reversible
transphosphorylation of two ADP molecules into ATP and
AMP and comprising, in conjunction with NDPK, an effi-
cient ATP-regenerating pathway in the human VF.
Moreover, soluble eN/CD73 mediates hydrolysis of AMP
into adenosine, whereas NTPDase and adenosine deaminase
Fig. 1 Study design. a Schematic illustrations of the cross section of the
eye and b the fundus of the eyes from healthy subjects and patients with
RRD, MH, pucker, non-PDR, and PDR. Surgical enrolment criteria for
diabetic vitrectomy were non-clearing vitreous hemorrhage, traction
retinal detachment, or diabetic macular edema with vitreomacular
traction. In the eyes with PDR, perfused neovessels were observed on
the retina or optic disk during vitrectomy. c Vitreous humors were
collected from the patients by manual aspiration into a syringe at the
start of the conventional three-port pars plana vitrectomy. d Sample
aliquots were subjected to analysis of intravitreal levels of ATP, ADP,
adenosine, and other biomarkers, as well as TLC-based enzymatic
assays. For purine-sensing assays, VFs were heat inactivated for 5 min
at 65 °C. For pictorial illustration, aliquots of [3H]ATP, [3H]ADP,
[3H]AMP, and [3H]Ado (∼1 μl each) were pooled, separated by TLC,
and developed by autoradiography. The arrows indicate the positions of
3H-labeled nucleotides and adenosine (Ado)
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seem not to contribute significantly to the intravitreal purine
metabolism (Fig. 2e).
Comparative analysis of intravitreal AK and eN/CD73
activities in diabetic vs. non-diabetic eyes
We then evaluated the pattern of ocular nucleotide homeosta-
sis at certain pathological conditions, by measuring the activ-
ities of eN/CD73 and AK in the VF from both non-diabetic
and diabetic patients. Detailed information on diabetic
mellitus, age, and gender distribution among the patients stud-
ied is provided in Table 1. Analysis of the glycemic status
confirmed that in comparison with a normal reference range
of 4–6 % determined in healthy persons, the levels of glycated
HbA1c were significantly elevated in blood of diabetic pa-
tients (Table 1).
The ability of VF to hydrolyse [3H]AMP (Fig. 3a, b)
and also to mediate its ATP-dependent phosphorylation
(Fig. 3c, d) varied substantially among the individuals.
No significant differences in intravitreal eN/CD73 activities
Fig. 2 Characterization of purine homeostasis in the human vitreous
fluid. a VF from RRD patients were pre-treated without and with
APCP or Ap5A and then incubated with [
3H]AMP, [3H]ADP, [3H]ATP,
and also with [3H]AMP plus ATP, as indicated. Mixture aliquots were
separated by TLC and developed by autoradiography. The arrows
indicate the positions of nucleotides and adenosine (Ado). The blanks
(Bl) show the radiochemical purity of tracer substrates in the absence of
VF. b Vitreous purine-converting activities were assayed using 3H-
labeled and unlabeled nucleotides and adenosine as substrates. Each
symbol represents one patient, and the vertical lines indicate the means
(n = 8). c The rates of [3H]AMP hydrolysis and ATP-mediated [3H]AMP
phosphorylation were determined in the VF from five RRD patients
before (open symbols) and after (closed symbols) centrifugation of the
samples and passing the obtained supernatants through 0.22-μm filters.
Enzymatic activities in b and c were expressed as nanomoles of 3H-
labeled substrate inactivated (left panels) or phosphorylated (right) by
milliliter of VF per hour. d VF samples were pre-treated with beads
coupled to antibodies against eN/CD73, AK1, and AK2, as well as
normal rabbit serum (NRS). The activities of eN/CD73 and adenylate
kinase (AK) were quantified from three assays, each performed with
VF pooled from three patients and expressed as the percentage of
control activity determined in the NRS-treated samples (mean ± SD,
total n = 9). **P < 0.01. e The scheme highlights the exchange
activities of adenine nucleotides and adenosine in the human vitreous.
Major converting pathways mediated through soluble eN/CD73, AK1,
and NDPK reactions have been identified and outlined in bold, while
NTPDase and adenosine deaminase (ADA) do not seem to contribute
significantly to the intravitreal purine homeostasis
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were determined among the groups studied; however, there
was a clear trend in diminished [3H]AMP hydrolysis in the
diabetic eyes (Fig. 3b, inset). On the contrary, VF from
diabetic patients were characterized by markedly elevated
rates of ATP-mediated [3H]AMP phosphorylation, with the
most striking up-regulation in AK activity being observed
in the cohort of PDR patients. Interestingly, additional sub-
group analysis revealed that all eyes operated due to MH or
pucker displayed low or undetectable AK activities
(Fig. 3d).
The activity of AK, but not eN/CD73, correlates with levels
of ATP; ADP; and other angiogenic, profibrotic,
and proteolytic factors in the eye
We have shown earlier that in comparison with non-diabetic
controls, VFs from DR patients contain higher concentrations
of adenine nucleotides [17], as well as Ang-2, VEGF, and other
angiogenic and inflammatory biomarkers [6]. More thorough
studies with expanded numbers of patients further demonstrat-
ed selective diabetes-related increases in ATP concentrations in
the VF, but not in the blood plasma, accompanied by ∼2–3-fold
increase in ATP/ADP ratios in the PDR and also non-PDR eyes
(Table 1). Most likely, the revealed increases in intravitreal ATP
occur locally in the diabetic eye, without any shifts in nucleo-
tide levels in the systemic circulation.
The non-parametric correlation analysis revealed the exis-
tence of positive correlations between intravitreal AK activity
and ATP and ADP levels, as well as MMP-9, TGFβ1, Ang-1,
and Ang-2 (but not VEGF and erythropoietin), with the
highest Spearman’s r coefficients being observed in the dia-
betic eyes (Fig. 4 and Supplementary Fig. 1). Interestingly,
while no significant differences in intravitreal adenosine con-
centrations were determined among the groups studied [17]
(also Table 1), there was a significant inverse correlation be-
tween this nucleoside and AK activity in the PDR eyes
(Fig. 4c). By contrast, eN/CD73 activity displayed relatively
poor or insignificant correlations with intravitreal concentra-
tions of purines and other mitogenic, vasculotropic,
profibrotic, and inflammatory biomarkers (Fig. 5 and
Supplementary Fig. 2).
Immunohistochemical analysis of eN/CD73 distribution
in the human retina
The innermost retina may serve as one of the major sources
of enzymes secreted to the VF. During histological prepara-
tion, the retina is known to be frequently detached from the
Fig. 3 Intravitreal nucleotide-converting enzymes in non-diabetic and
diabetic eyes. Representative autoradiographic images depict the pattern
of [3H]AMP metabolism in the VF from three RRD (1–3) and one PDR
(4) patients, as determined in the absence (a) and presence (c) of γ-
phosphate-donating ATP. The arrows indicate the positions of
nucleotide standards and adenosine (Ado). The blanks (Bl) show the
radiochemical purity of [3H]AMP. Specific eN/CD73 (b) and AK (d)
activities were quantified by scintillation β-counting in the VF from the
indicated groups of patients and presented as scatterplots. Each dot
represents an individual patient, and the horizontal line indicates the
median. The ordinates show the catalytic activities expressed as
nanomoles of [3H]AMP hydrolyzed (b) or phosphorylated (d) by
milliliter of VF per hour. **P < 0.01
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wall of the eye and the plane of cleavage is usually between
the photoreceptors and the retinal pigment epithelium.
Nevertheless, well-preserved paraffin sections of human ret-
ina were available for histochemical staining, and the obtain-
ed results demonstrated the abundant expression of eN/
CD73 in the outer nuclear layer but not in the ganglion cells
(Fig. 6).
Discussion
We have identified soluble enzymes, eN/CD73, AK
(mainly comprising of AK1 isoform), and NDPK, in
the human VF and further demonstrated that AK activ-
ity is selectively up-regulated in the PDR patients, as
compared with non-diabetic controls. Constitutive
Fig. 4 Correlation analysis
between AK activity and various
biomarkers in human vitreous.
The activity of AKwas assayed in
VF from non-diabetic and
diabetic eyes and further
correlated with intravitreal
concentrations of ATP (a), ADP
(b), adenosine (c), and VEGF (d).
Similar analysis was also
performed for TGFβ1,
erythropoietin (EPO), MMP-9,
Ang-1, and Ang-2 (see
Supplementary Fig. 1), and e
summarizes the non-parametric
Spearman’s correlation
coefficients (Spearman’s r)
computed to investigate the
relationship between AK activity
and these intravitreal biomarkers.
nd not determined due to
insufficient number of
samples.*P < 0.05 and
**P < 0.01
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presence of intravitreal nucleotide-converting activities,
together with wide expression of purinergic receptors
and ecto-enzymes in the retina and other ocular struc-
tures, comprises a novel and heretofore unrecognized
network coordinately regulating nucleotide homeostasis
and signaling in the eye.
The discovery of soluble purinergic activities is not a
unique phenomenon. A broad spectrum of enzymes (includ-
ing eN/CD73 and AK1) circulates in the human and murine
bloodstream [29, 32] and can be secreted by vascular endo-
thelial, hematopoietic, epithelial, and tumor cells [19, 33] and
also by sympathetic nerves [34] in response to the application
Fig. 5 Correlation analysis
between eN/CD73 activity and
various biomarkers in human
vitreous. The activity of eN/CD73
was assayed in VF from non-
diabetic and diabetic eyes and
further correlated with intravitreal
concentrations of ATP (a), ADP
(b), adenosine (c), and VEGF (d).
Similar analysis was also
performed for TGFβ1,
erythropoietin (EPO), MMP-9,
Ang-1, and Ang-2 (see
Supplementary Fig. 2), and e
summarizes the non-parametric
Spearman’s correlation
coefficients (Spearman’s r)
computed to investigate the
relationship between eN/CD73
and these intravitreal biomarkers.
nd not determined due to
insufficient number of samples.
*P < 0.05 and **P < 0.01
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of shear forces and other mechanical and chemical stimuli.
While the origin of intravitreal enzymes remains unknown,
it is pertinent to note that eN/CD73 is abundantly expressed
in the sensory retina, neuronal cells, corneo-scleral layer, and
other eye entities [26, 35] (also current study). The cytosolic
enzyme AK1 and its membrane-associated isoform AK1β are
also present in high-energy-demanding tissues, including the
brain [19, 36], neuronal cells [37], and outer segments of
retina [38]. It may be speculated that certain portions of
(ecto)enzymes can be released into the vitreous cavity upon
light-evoked neuronal stimulations; dark-light transitions; and
during mechanical perturbations caused by incessant eye
movements, blinking, and variations in the vascular tone and
intraocular pressure.
High concentrations of ATP are known to accelerate apo-
ptosis of photoreceptor cells via ligation of ATP-specific
P2X7 receptors [16, 39] and in addition, mediate neurodegen-
eration, gliosis, neovascularization, inflammation, and vascu-
lar leakage [12, 25]. In felines and rodents, intravitreal admin-
istration of ATP induced photoreceptor degeneration, retinal
neural remodeling, and Müller cell gliosis, with most of these
pathological changes continuing out to 12 weeks post-
injection [40]. The identification of intravitreal AK adds an-
other level of complexity to our understanding of ATP-
mediated retinal dysfunction and degeneration. Marked up-
regulation of soluble AK in the PDR eyes with advanced
retinal hemorrhage may indicate on massive leakage of AK,
along with ATP and other transmitters, by injured neurons,
glial cells, or extravasated blood cells in the course of retinal
degeneration and blood clotting. In the absence of soluble
NTPDases, AK and NDPK comprise the predominant
nucleotide-converting pathway in the VF by mediating
continuous resynthesis of the released ATP through sequential
phosphotransfer reactions. Interestingly, in aDrosophilamod-
el of human tauopathy, the retinal expression of human AK1
severely exacerbated a rough eye phenotype and contributed
to an abnormal tau-mediated neurodegeneration in transgenic
flies [37]. Vitreous and humoral fluids and tears also contain
diadenosine polyphosphates (ApnA; n = 2–6), a family of
dinucleotides with diverse physiological properties in the
eye [13] and other tissues [41]. ApnA are thought to exert their
actions either directly by means of P2X and P2Y receptors or
via ecto-enzymatic conversion into ATP and other biological-
ly active metabolites [13, 19, 41]. Potent inhibition of both
membrane-bound [31] and soluble [32] (present study) AK by
Ap5A may provide an alternative explanation of the therapeu-
tic effects of this bisubstrate analog, via prevention of exces-
sive AK-mediated formation of ATP in the eye.
Data on the presence of eN/CD73 in the VF and specific
enzyme distribution along the sensory retina further extend
our knowledge on the purinergic mechanisms in the human
eye. Taking into account the involvement of adenosinergic
signaling in modulation of the light responses of photorecep-
tors, retinal hyperemia, and protection of neurons from hyper-
excitation and glutamate toxicity [8, 11, 14], it may be hypoth-
esized that eN/CD73-mediated generation of adenosine repre-
sents an important constituent of purinergic signaling machin-
ery in the healthy retina. Recent identification of eN/CD73 as
a novel biomarker of the early stages of the photoreceptor
lineage and the increased integration of transplanted CD73-
enriched photoreceptor precursors in the adult mouse retina
[35, 42, 43] also provide sufficient background for manipula-
tion of ocular adenosine homeostasis as a promising strategy
for stem cell-derived replacement therapy. However,
prolonged increases in adenosine concentrations may be inju-
rious to the retina, mainly due to enhanced formation of su-
peroxide radicals secondary to adenosine metabolism [8, 14].
Surprisingly, despite the abundant eN/CD73 expression on the
rod-and-cone-containing photoreceptor cells (see Fig. 6b), en-
dogenous adenosine and its receptors were shown to be com-
partmentalized in the ganglion cells and inner plexiform layer
[8]. This apparent discrepancy presumably reflects high turn-
over rate of (extra)cellular purines in the outer retinal seg-
ments, with only transient formation of adenosine as an inter-
mediate metabolite of the nucleotide-inactivating chain.
Assessment of the physiological relevance of intravitreal
enzymes is another important issue. Given that the VF repre-
sents the largest structure within the eye occupying about
80 % of the ocular volume [44], soluble enzymes could com-
prise an important auxiliary effector system for tuned regula-
tion of nucleotide concentrations in the eye. For instance, large
surface-to-volume ratio of the retina may facilitate diffusion of
soluble eN/CD73 and its metabolite adenosine from the vitre-
ous core to the vitreoretinal interface, thereby contributing to
the known phenomenon of relative tolerance and functional
Fig. 6 Distribution of eN/CD73 in human retina. Formalin-fixed,
paraffin-embedded human retinal sections were stained with rabbit α-
CD73 antibody (b) or normal rabbit serum (NRS) as a negative control
(c). Tissue sections were also stained with hematoxylin and eosin (H&E)
(a). ILM inner limiting membrane, GC ganglion cell, INL inner nuclear
layer, IPL inner plexiform layer, ONL outer nuclear layer. Scale bar
200 μm
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recovery of the inner retina even after extended periods of
acute ischemia and hypoxia [1]. The balance between
membrane-associated and soluble enzymes can be further
shifted under certain pathogenic states, including inflamma-
tion, hypoxia, oxidative stress, vascular lesion, and age- or
diabetes-related liquefaction of the vitreous body. In fact,
since the retina is one of the most metabolically active and
oxygen-sensitive tissues in the body, it is continuously at risk
for developing tissue ischemia and hypoxia, especially during
DR, age-related macular degeneration, and other pathological
states [1, 4]. While the expression levels of ecto-nucleotidases
in the retina of diabetic patients still remain to be elucidated, in
the cardiovascular system, endothelial ecto-nucleotidase ac-
tivities were shown to be diminished under conditions of myo-
cardial infarction and ischemia-reperfusion injury [20, 45],
atherogenesis [46], chronic hypoxia [47], hypothermia [48],
transplantation, and stroke [49], accompanied by elevated
levels of intravascular ATP and ADP and profound shifts in
vascular permeability, blood flow, and local pro-coagulant
responses. One of the promising strategies to offset the re-
duced nucleotide-scavenging effectiveness of injured vascular
endothelium includes the administration of recombinant hu-
man NTPDase1/CD39 [48, 49] or soluble NTPDase3
(APT102) [45] for anti-platelet, anti-inflammatory, and
cardioprotection therapies.
On the other hand, concurrently elevated soluble AK activ-
ity and ATP concentration in the PDR eyes (current study),
together with feed-forward inhibition of eN/CD73-mediated
hydrolysis of AMP into adenosine by precursor nucleotides
ATP and ADP [31], might serve as unfavorable pathogenic
factors maintaining chronically elevated ATP levels and trig-
gering spatial propagation of inflammatory responses into the
surrounding retina far distant from the site of focal detach-
ment. The contribution of AK-mediated ATP formation to
the pathogenesis of DR is further ascertained by the existence
of positive correlations between the AK activity and other
angiogenic (Ang-1), profibrotic (TGFβ1), and proteolytic
(MMP-9) factors, with the highest Spearman’s r coefficients
being observed in the PDR eyes (see Fig. 4). Interestingly,
previous proteomic analysis of VF from PDR and non-PDR
patients has also shown that the quantitative proteome differs
between these two disease states, with a number of immuno-
modulatory, pro-apoptotic, and growth factor molecules being
up-regulated only in the PDR eyes [7]. While another intra-
vitreal enzyme eN/CD73 displayed relatively poor correla-
tions with concentrations of purines and other biomarkers, it
is worth mentioning the existence of positive interrelations
between eN/CD73 activity and EPO levels in non-diabetic
and non-PDR, but not in PDR, eyes (see Fig. 5). EPO, a
secreted glycoprotein of the type I cytokine family, plays a
central role in VEGF-independent protection of retinal gangli-
on cells and photoreceptors via pleiotropic mechanisms [1, 5].
Since both EPO [1] and eN/CD73 [23] expressions can be
regulated by hypoxia-inducible transcription factor-1α
(HIF1α), further studies are required to elucidate how these
molecules regulate tissue oxygenation and promote survival
and recovery of photoreceptor cells in certain compensatory or
synergistic manners.
In summary, the identification of soluble intravitreal en-
zymes provides novel insights into the mechanisms that influ-
ence purinergic signaling pathways in the human eye. Data on
concurrently elevated AK activities and ATP levels in the VF
from PDR patients suggest selective diabetes-related shifts in
ocular purine homeostasis from generation of the anti-
inflammatory adenosine toward a pro-inflammatory ATP-
regenerating phenotype. It is conceivable but remains to be
experimentally proven that directional restoration of the
adenosine-generating capacity in the diabetic eye via increas-
ing eN/CD73 expression on photoreceptor cells or intraocular
application of soluble nucleotidases, in combination with
blocking ofATP re-synthesis by using selective AK inhibitors,
might open up new possibilities in the development of inno-
vative enzyme-targeted therapeutic approaches for prevention
and treatment of DR.
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